A study published in Nature investigates how gut bacteria influence cancer immunotherapy outcomes. Researchers found that microbial antigens can mimic self-antigens through antigenic mimicry, affecting immune checkpoint blockade (ICB) therapies like anti-PD-1 treatment. In mouse models, the presence of segmented filamentous bacteria (SFB) markedly improved responses to anti-PD-1 treatment despite the large gut-skin distance. The findings suggest gut microbiome composition may explain why some patients respond to immunotherapy while others don't, offering potential new directions for improving CAR T-cell and other cancer immunotherapies.
Sort: